Stocktoria
GRAIL, Inc. GRAL
GRAIL, Inc. (GRAL) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $147.2M at a -277.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-05 | Goldman Sachs | Neutral (init) |
| 2026-05-06 | TD Cowen | Buy (main) |
| 2026-05-06 | Piper Sandler | Neutral (main) |
| 2026-04-10 | Mizuho | Neutral (init) |
| 2026-04-10 | Piper Sandler | Neutral (init) |
| 2026-03-30 | Guggenheim | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.299 |
| Retained earnings / assets | -3.495 |
| EBIT / assets | -0.192 |
| Equity / liabilities | 7.49 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| GRAL | GRAIL, Inc. | 4/9 | -2.86 | — | +17.2% |
| BDSX | BIODESIX INC | 3/9 | -19.59 | — | +24.1% |
| BNR | Burning Rock Biotech Ltd | 5/9 | -11.46 | — | +9.2% |
| PSNL | Personalis, Inc. | 3/9 | 0.31 | — | -17.7% |
| XGN | EXAGEN INC. | 3/9 | -14.91 | — | +19.7% |
| CFOR | CapForce Inc. | 2/9 | -14.09 | 1 | — |
| BGLC | BioNexus Gene Lab Corp | 4/9 | 13.26 | — | — |
About GRAIL, Inc.
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
FAQ
Is GRAL financially healthy?
GRAIL, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does GRAL pay a dividend?
No, GRAIL, Inc. does not currently pay a dividend.
How profitable is GRAL?
In FY2025, GRAIL, Inc. had a net margin of -277.5% and a return on equity of -15.8%.
What is the analyst price target for GRAL?
The average Wall-Street price target for GRAIL, Inc. is $66.00, about 4.3% below the recent price, from 8 analysts (consensus: buy).
Is GRAL a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on GRAIL, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.